Continuing a TNF Inhibitor Through Consolidation Immunotherapy for Limited-Stage SCLC
A newly established survival benefit for consolidation durvalumab after chemoradiation in limited-stage small cell lung cancer meets a patient already stable for years on a biologic for psoriatic arthritis. The disagreement is whether to touch a medication regimen that isn't broken to make room for one that just became standard of care.
Gerald T., 71, took up birdwatching the week he retired from thirty years as an accountant, and keeps a life list he updates most mornings from his back porch before the neighborhood wakes up. Psoriatic arthritis, diagnosed in his fifties, has been fully controlled for the past six years on adalimumab, with no flares and no joint symptoms to speak of; his skin, aside from a few faint patches on his elbows, shows no active plaques — and those elbow patches matter more than they look like they should, because they are not nothing, they are his personal floor, the thing any post-durvalumab skin change would have to be measured against rather than compared to clear skin. A week of hemoptysis led to a chest CT and then a biopsy confirming limited-stage small cell lung cancer, confined to one hemithorax and treatable with curative intent; he completed concurrent chemoradiation five weeks ago and has recovered well, back on the porch with his binoculars most mornings, aside from a persistent mild cough his radiation oncologist has called an expected, slowly improving finding.
He is now in the window where ADRIATIC changed practice: consolidation durvalumab after chemoradiation in limited-stage disease produced a substantial, previously unseen survival benefit in exactly this setting, enough to make it the new standard rather than an option to discuss. The complication is his adalimumab, which he has continued without interruption through diagnosis, chemoradiation, and recovery, with his rheumatologist seeing no reason yet to change it. TNF inhibition works by damping the same inflammatory signaling that checkpoint blockade is trying to unleash, at least in theory, and real-world data in patients on baseline immunosuppression for autoimmune disease starting checkpoint inhibitors, most of it from melanoma populations including Menzies and colleagues’ cohort, show a real but generally manageable flare rate without clearly blunted anti-tumor benefit. Whether that reassurance transfers to him specifically is the harder question: those cohorts were assembled from patients with active or recently active autoimmune disease, and Gerald has not had a flare in six years. He sits at the quiet end of a population defined by not being quiet — which cuts both ways, since the same six years of stability that make a flare less likely are also six years of a TNF inhibitor doing exactly what checkpoint blockade is about to work against.
A drug that works, meeting a drug that just became standard
Start durvalumab and leave the adalimumab exactly as it is. ADRIATIC’s benefit was substantial enough to become the new standard of care in this setting, and there is no strong signal that stable, low-level immunosuppression for a controlled autoimmune condition meaningfully blunts checkpoint inhibitor efficacy. Touching a medication that has kept him flare-free for six years, on the theoretical concern that it might interfere with a drug we have not even started yet, risks trading a real, working control for a hypothetical benefit.
I agree the theoretical mechanism concern about blunted efficacy is exactly that — theoretical, not demonstrated.
But there is a separate, more concrete problem: adalimumab’s own immunosuppressive effect can mask or delay recognition of an emerging immune-related adverse event. If he develops new joint pain or gastrointestinal symptoms on durvalumab, the reflex will be to attribute it to his psoriatic arthritis or to the biologic itself, not to a new checkpoint-inhibitor toxicity — and that attribution error is exactly how an early, manageable irAE becomes a late, severe one. This is not an argument to stop adalimumab, it is an argument that whoever is watching him needs to know his baseline well enough to notice a real change.
Both of you are right, and neither position actually requires touching his adalimumab. The data on tapering or holding a biologic before starting a checkpoint inhibitor is not established as protective, and an abrupt change in a drug that has kept him controlled for six years is itself a real risk of precipitating the exact flare everyone wants to avoid, for no proven benefit.
Continue adalimumab unchanged, start durvalumab per ADRIATIC’s protocol, and build the flare-versus-irAE distinction directly into his follow-up: any new joint or gastrointestinal symptom gets evaluated with both possibilities explicitly on the differential from the first visit, not defaulted to whichever diagnosis is more familiar to whoever happens to see him that day.
Agreed: continue adalimumab unchanged, start durvalumab per ADRIATIC’s protocol, and document explicitly that any new joint, skin, or gastrointestinal symptom is to be evaluated for both a psoriatic arthritis flare and an emerging immune-related adverse event from the first visit, with rheumatology and oncology co-managing any new symptom rather than seeing him sequentially.